Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
about
Chutes and ladders in hepatitis C nucleoside drug developmentChanging the face of hepatitis C management - the design and development of sofosbuvirDirect-acting antivirals for chronic hepatitis C.Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.Direct-acting antivirals for chronic hepatitis C
P2860
Q26998630-085D40AC-ED80-4F6B-8BDA-D9CEB43C17C1Q27011203-D0E74895-0668-4C6D-8348-D3BAA28E0833Q34557595-05D26DD5-FF99-4E4B-BE43-9581ACC049B4Q36667039-2D9411E1-A816-441A-9D3C-63F67BE8ED3CQ38245128-BACDB4F0-A925-43C6-8832-4DEFE1510ECBQ40326326-BC9059B7-CDD6-4BC0-8874-33EC8575435BQ40401740-B3D6B5EB-BF85-4DEC-B5E1-7D1BBF7E9F5AQ42271739-43873B2E-D336-463B-B0F4-17C53F8BDFD6Q50283110-7DBDDD81-57EB-4802-89F0-31130C264974Q57389418-F8A2D64C-765E-423B-B4D4-F1116042E677
P2860
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@ast
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@en
type
label
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@ast
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@ast
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@en
P2093
P2860
P356
P1476
Pharmacokinetics, pharmacodyna ...... chronic hepatitis C infection.
@en
P2093
Efsevia Albanis
Eric Lawitz
Jill M Denning
Maribel Rodriguez-Torres
Melanie Cornpropst
Michelle M Berrey
William T Symonds
P2860
P304
P356
10.1128/AAC.01263-12
P407
P577
2012-12-21T00:00:00Z